Expanded access program in Tumor hyperinsulinism
83 evidence topics · 17 sources
Objective
Objective of the peer-reviewed case series: insulinoma and cervical neuroendocrine carcinoma
“We retrospectively report outcomes from compassionate use of ersodetug in 8 individuals with refractory hypoglycemia due to tumor HI.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“this case series retrospectively reports on the experience of 8 individuals with refractory hypoglycemia due to tumor HI (metastatic insulin-producing tumors) who were treated with ersodetug on a compassionate use basis via an expanded access program (EAP).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Objective of the ENDO 2026 case series poster
Objective of the single published case: metastatic insulinoma
“We report the successful use of RZ358, a novel human anti–insulin receptor monoclonal antibody, in a patient with metastatic insulinoma in whom severe, refractory hypoglycemia developed after peptide receptor radionuclide therapy with lutetium Lu 177 dotatate.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Purpose of the intermediate-size cohort expanded access program: insulinoma and NICTH
Location and study date
Enrollment period, data cutoff, and countries in the peer-reviewed case series
“Eight individuals with refractory hypoglycemia secondary to HI whose glycemic needs were not adequately managed by standard-of-care therapies were enrolled in the EAP beginning in November 2022; data were collected until the data cutoff of August 2025.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“were enrolled in the EAP in the United States (n = 7) and the Netherlands (n = 1)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
First patient treated at a single U.S. center under FDA emergency use authorization
“We obtained emergency use authorization from the Food and Drug Administration, approval from the institutional review board of Beth Israel Deaconess Medical Center, and written informed consent from the patient.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Investigators in the United States and Europe, as stated by the company in January 2026
Status, dates, and location of the intermediate-size cohort expanded access program
| Field | Quoted record |
|---|---|
| Expanded access status | “Available” |
| Other study ID number | “RZ358-303” |
| First submitted | “2025-11-21” |
| First posted | “2025-12-04” |
| Last update posted | “2026-10-07” |
| Location | “New Orleans, Louisiana, United States, 70112” |
Program continuing after completion of upLIFT enrollment
Study design
Retrospective case series of single-patient compassionate use requests
“Enrollment was initiated by a treating physician through a named patient request (single-patient investigational new drug application) to the country health authority and was approved by local institutional review board, if required.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Written informed consent was obtained from all individuals before treatment initiation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Change from an earlier compassionate use framework to a tumor HI-specific framework
“The first 2 individuals were enrolled under an earlier compassionate-use program framework; a subsequent, tumor HI–specific framework was implemented during the course of the third patient's treatment and applied to all remaining individuals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The updated framework incorporated a higher weekly dose that had shown superior effectiveness in early experience” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Overlap of the first patient with the published single case
“For Patient 1, the continuous glucose monitoring (CGM) and glucose infusion rate (GIR) data for the 90-day pre- and post-treatment windows presented herein also were previously reported in a single case report” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“all other efficacy data for this patient are new.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This patient was the first to receive ersodetug for tumor HI, with detailed results previously reported in a case report” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Role of the expanded access data in Breakthrough Therapy Designation and the upLIFT redesign
Design of the intermediate-size cohort expanded access program
| Field | Quoted record |
|---|---|
| Official title | “Intermediate-Size Cohort EAP for Ersodetug in Patients With Refractory Hypoglycemia Due to Tumor-Associated Hyperinsulinism (Tumor HI) Who Are Unable to Participate in a Clinical Trial” |
| Study type | “Expanded Access” |
| Expanded access type | “Intermediate-size Population” |
| Condition | “Tumor-associated Hyperinsulinism (Tumor HI)” |
| Sponsor | “Rezolute” |
Eligibility criteria
Eligibility in the peer-reviewed case series
“Individuals were eligible regardless of tumor type, prior therapies, or comorbidities, provided they were clinically stable for infusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All listed diagnoses were confirmed by relevant laboratory, imaging and pathology over the treatment courses and prior to initiating ersodetug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Inclusion criteria of the intermediate-size cohort expanded access program: insulinoma and NICTH
Exclusion criteria of the intermediate-size cohort expanded access program
Age and sex eligibility of the intermediate-size cohort expanded access program
| Field | Quoted record |
|---|---|
| Ages eligible | “18 Years and older” |
| Sexes eligible | “All” |
Treatment
Dose, route, and schedule in the peer-reviewed case series
“Ersodetug was administered intravenously over 30 minutes at an initial dose of 6 or 9 mg/kg, given either weekly or every other week initially, followed by a frequency of every 2-5 weeks, as appropriate, at the discretion of the treating physician.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dose adjustments, including titration and changes in dosing frequency, were made based on glycemic response, tolerability, and clinical course.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After exploratory dose-ranging in the first 2 participants, the initiation dose regimen was standardized in subsequent participants to 9 mg/kg weekly, followed by de-escalation as indicated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One participant required escalation from 9 to 12 mg/kg every other week.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Concomitant standard-of-care and tumor-directed therapy
“Supportive therapies, including use of ongoing standard-of-care antihypoglycemic treatments, were noted and recorded.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Individuals resumed tumor-directed therapies or procedures as deemed appropriate by the multidisciplinary clinical care team, and these interventions were systematically recorded as part of the observational dataset.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Drug supplied at no cost by the manufacturer
Dose regimen by patient in the company table of 9 patients
| Patient | Ersodetug dose regimen (dose/frequency) |
|---|---|
| Patient 1 | “6-9 mg/kg every 1-4 weeks” |
| Patient 2 | “6-9 mg/kg every 1-2 weeks” |
| Patient 3 | “9 mg/kg, every 1-2 weeks” |
| Patient 4 | “9-12 mg/kg every 1-2 weeks” |
| Patient 5 | “9 mg/kg every 1-3 weeks” |
| Patient 6 | “9 mg/kg every 1-2 weeks” |
| Patient 7 | “6-9 mg/kg every 1-2 weeks” |
| Patient 8 | “9 mg/kg every 1-2 weeks” |
| Patient 9 | “9 mg/kg every 1-3 weeks” |
Dosing in the ENDO 2026 case series poster
Intervention in the intermediate-size cohort expanded access program
| Field | Quoted record |
|---|---|
| Intervention | “Drug: Ersodetug (9 mg/kg) + SOC” |
| Description | “Open-Label Participants with a diagnosis of Tumor HI (insulin- or IGF-producing tumors)” |
Study outcomes
Rationale for using discontinuation of parenteral glucose as the primary outcome
No prespecified primary outcome: efficacy assessments centered on glucose infusion rate
“Assessments of efficacy focused on changes in GIR (since most participants initially required parenteral dextrose to correct refractory hypoglycemia) and also included assessments of hypoglycemia by CGM (described below), number of hospitalization days in the month before and after ersodetug initiation, and overall survival.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eastern Cooperative Oncology Group (ECOG) performance status was used to assess functional ability.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ersodetug dosing regimen, treatment duration, and safety observations (serious adverse events and drug-related serious adverse events) were also recorded and assessed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Parenteral dextrose at baseline masks hypoglycemia measured by continuous glucose monitoring
“Most individuals were receiving parenteral dextrose during baseline, which by intent likely ameliorated hypoglycemia, thus masking the severity of baseline glycemic measures by CGM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Therefore, changes from baseline in CGM should be interpreted accordingly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Continuous glucose monitoring outcomes and windows
“CGM data were analyzed for mean sensor glucose and percent of time in predefined glycemic ranges (eg, <70 mg/dL, <54 mg/dL, and >180 mg/dL).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Baseline for CGM purposes was defined as the period up to 90 days before the first dose of ersodetug, and the evaluable window was defined as the period up to 90 days after initiation; longer follow-up CGM data were included in a sensitivity analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Its pharmacokinetic characteristics informed selection of a 90-day evaluable window during which drug concentrations were expected to be at steady-state for most individuals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Parenteral infusion as a barrier to discharge and to tumor-directed therapy
“Supportive strategies such as frequent carbohydrate intake or continuous parenteral dextrose infusion are often required but are burdensome and do not provide durable control, and parenteral infusions may prevent hospital discharge.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These functional gains enabled most individuals to pursue tumor-directed therapies, including chemotherapy, surgery, and hepatic arterial embolization, underscoring the importance of glycemic stabilization as a prerequisite for oncologic care in this population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Glucose infusion rate as the focus of the ENDO 2026 case series analysis
Glucose infusion rate assessment shared with the upLIFT primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Peer-reviewed case series: 8 participants
“Eight adults (4M/4F; 24-74 years; Eastern Cooperative Oncology Group [ECOG] 1-3) received ersodetug for insulin-secreting tumors (metastatic insulinoma, n = 7; cervical neuroendocrine carcinoma, n = 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All 8 individuals had CGM data available.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Company table filed with the SEC: 9 patients
ENDO 2026 company release: 9 patients with malignant insulinoma and non-islet cell tumors
Total patients treated under the program, as stated by the company: more than 10 to 13
Description of analysis sets
Analysis population and evaluation periods in the peer-reviewed case series
“In this retrospective analysis, observational data were collected until August 2025 (or earlier treatment discontinuation) in all individuals who received at least one infusion of ersodetug and had available follow-up data.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For standardization of glycemic assessments, baseline was defined as the period up to 90 days prior to ersodetug initiation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The evaluable period was defined as the time from ersodetug initiation until the data cutoff (August 2025) or treatment discontinuation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Parenteral glucose subset: 7 of 8 participants
Paired nonparametric comparisons without formal hypothesis testing
“Changes in percent time in glycemic ranges and medication counts were assessed from paired comparisons of the baseline period (up to 90 days) with the post-initiation evaluable period (up to 90 days) using the Wilcoxon-signed rank test in R.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“95% intervals could not be constructed due to the sample size [N = 8] and discrete nature of the test” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Strength of statistical evidence was evaluated using nominal P-values, but no formal or prespecified hypothesis testing was conducted due to the retrospective nature of the report and limited sample size.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A statistical analysis plan with additional details of the statistical methods was developed after primary data analyses and is available in the Supplemental Appendix” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Treatment duration, dosing de-escalation, and deaths in the peer-reviewed case series
“Most individuals (n = 6/8) were able to decrease the dosing frequency of ersodetug after hospital discharge.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median treatment duration with ersodetug of 11.5 months (range 5-17 months; ongoing in 2 individuals) also corresponded to patient lifespan and overall survival in the setting of metastatic disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the individuals who died (n = 6), tumor progression and sepsis were cited as the cause, unrelated to the investigational drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment duration and survival by patient in the company table of 9 patients
| Patient | Total duration of ersodetug therapy (months) | Overall survival (months) |
|---|---|---|
| Patient 1 | “13” | “14” |
| Patient 2 | “5” | “5” |
| Patient 3 | “5” | “5” |
| Patient 4 | “14” | “14” |
| Patient 5 | “22 (ongoing)” | “22 (living)” |
| Patient 6 | “18 (ongoing)” | “18 (living)” |
| Patient 7 | “6” | “6” |
| Patient 8 | “1.5” | “1.5” |
| Patient 9 | “10” | “10” |
Critically ill patient who died of sepsis before response could be assessed: company table
First two patients still receiving treatment in October 2023
Baseline characteristics
Demographics and clinical characteristics in the peer-reviewed case series
“All individuals were White; 7 identified as non-Hispanic and one as Hispanic.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Seven individuals had metastatic insulinoma and one had neuroendocrine carcinoma of the cervix.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The cohort was characterized by predominantly metastatic disease with substantial hepatic involvement and variable but often abnormal liver biochemistry, along with renal function ranging from normal to mildly impaired at the time of ersodetug initiation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hospitalization at entry stated in the text of the peer-reviewed case series
Prior therapy, home parenteral nutrition, performance status, and hospice consideration at entry
“All individuals had received and were refractory to at least 3 standard-of-care therapies, including diazoxide, short- and long-acting somatostatin analogs, everolimus, and/or corticosteroids.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two individuals initiated ersodetug prior to hospitalization, including one receiving continuous carbohydrate supplementation via home TPN.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Four of the 8 individuals had a baseline ECOG score of 3, 1 had an ECOG of 2, and 3 had an ECOG of 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two individuals were under hospice consideration at baseline due to refractory hypoglycemia, progressive disease, and lack of remaining tumor-directed treatment options.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Demographics, tumor, and organ function by patient in the peer-reviewed case series
Hospitalization, performance status, and prior antihypoglycemic therapy by patient in the peer-reviewed case series
Baseline characteristics by patient in the company table of 9 patients
| Characteristic | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | Patient 9 |
|---|---|---|---|---|---|---|---|---|---|
| Gender (M/F) / age (years) | “M / 55” | “F / 50” | “F / 50” | “F / 43” | “M / 74” | “M / 62” | “M / 74” | “M / 53” | “M / 24” |
| Diagnosis | “Metastatic Insulinoma” | “Metastatic Insulinoma” | “Neuroendocrine Carcinoma of the Cervix” | “Metastatic Insulinoma” | “Metastatic Insulinoma” | “Metastatic Insulinoma” | “Metastatic Insulinoma” | “Metastatic Proinsulinoma” | “Metastatic Insulinoma” |
| Number of antihypoglycemic therapies at enrollment | “4” | “3” | “3” | “4” | “4” | “3” | “5” | “2” | “4” |
| GIR at ersodetug initiation (mg/kg/min) | “6.0” | “7.0 (home TPN)” | “5.1” | “6.2” | “4.9” | “n/a (ambulatory)” | “5.6” | “Unknown amount” | “3.1” |
| Length of hospitalization before ersodetug (days) | “28” | “n/a (ambulatory)” | “15” | “49” | “34” | “n/a (ambulatory)” | “4” | “Unknown duration” | “16” |
| Baseline ECOG | “3” | “2” | “3” | “3” | “3” | “1” | “1” | “3” | “1” |
Patients and tumor types in the NANETS 2024 poster
| Patient | Gender | Age | Tumor type |
|---|---|---|---|
| Patient 1 | “M” | “55” | “Metastatic Insulinoma” |
| Patient 2 | “F” | “50” | “Metastatic Insulinoma” |
| Patient 3 | “F” | “50” | “Metastatic Insulin-Secreting Tumor (Cervical Primary)” |
| Patient 4 | “F” | “43” | “Metastatic Insulinoma” |
| Patient 5 | “M” | “74” | “Metastatic Insulinoma” |
Parenteral dextrose and hospital setting at entry in the NANETS 2024 poster
Single published case: presentation, tumor, and biochemistry
“A 55-year-old man presented with a 5-month history of abdominal pain and weight loss.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A liver biopsy revealed a pancreatic neuroendocrine tumor” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“with a pathogenic MEN1 mutation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hormonal analysis, performed when the venous glucose level was 41 mg per deciliter (2.3 mmol per liter), revealed inappropriately high levels of insulin, at 45 μIU per milliliter (312 pmol per liter; reference value, <19.6 μIU per milliliter [141 pmol per liter]); C-peptide, at 6.5 ng per milliliter (reference range, 0.80 to 3.85); and proinsulin, at 453 pmol per liter (reference value, <18).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Single published case: refractory hypoglycemia on maximal therapy before ersodetug
“Intravenous 50% dextrose solution was infused through a central line, at a rate of up to 60 ml (30 g) per hour, which reflects very high glucose use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Despite enteral nutrition support and treatment with high-dose diazoxide, everolimus, dexamethasone, pasireotide, and glucagon, the patient remained hypoglycemic, with up to 58% of all sensor glucose values in each 24-hour period being less than 70 mg per deciliter [3.9 mmol per liter] and up to 19% being less than 54 mg per deciliter (3.0 mmol per liter)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy results
Summary of glycemic outcomes in the peer-reviewed case series
“Most patients experienced improved glycemic control, including discontinuation of parenteral glucose in 6 of the 7 applicable patients (median, 4.5 days) and a 35.6% relative reduction from baseline in time in hypoglycemia (<70 mg/dL) by continuous glucose monitoring (mean 12.4-8.0%; pseudo-median paired change of -3.8 percentage points [90% CI, −8.2 to −1.1]; P = .02).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Discontinuation of parenteral glucose: 6 of 7 participants
“Six of 7 individuals on parenteral glucose support at baseline discontinued it within the 90-day post-therapy window (median time, 4.5 days), which allowed for subsequent reductions in other standard-of-care antihypoglycemic therapies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One individual on home TPN initiated ersodetug contemporaneously with ablation of primary hepatic metastases, ultimately achieving a 50% reduction in intravenous carbohydrate support after dose escalation of ersodetug to 9 mg/kg biweekly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Number of antihypoglycemic therapies before and after initiation
Time to discontinuation of each antihypoglycemic therapy by patient (days unless stated)
Hospital discharge, tumor-directed therapy, performance status, and survival by patient
Time below 70 mg/dL, time below 54 mg/dL, and hyperglycemia by continuous glucose monitoring
“Seven of 8 individuals achieved a reduction in percent time in hypoglycemia, with a mean decrease from 12.4% at baseline to 8.0% after receiving ersodetug (35.6% relative reduction), equating to a median absolute change of −3.8% (90% CI, −8.2 to −1.1; P = .02)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Percent time in Level 2 hypoglycemia (<54 mg/dL) also trended numerically lower, with a mean decrease from 2.6% at baseline to 1.9% after receiving ersodetug (median absolute change of −0.5%; 90% CI, −2.9 to 1.3; P = .38).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Reductions in overnight percent time in overall and Level 2 hypoglycemia were also observed, but statistical evidence was limited.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No hyperglycemia-related adverse events or need for insulin were reported.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Continuous glucose monitoring parameters over 24 hours, by day, and by night
Continuous glucose monitoring sensitivity analysis
“In a sensitivity analysis that incorporated all available CGM data beyond the initial 90-day windows for patients with evaluable recordings, clinical patterns remained consistent with the primary analysis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hospital discharge and tumor-directed therapy after initiation
“The median time to hospital discharge after initiation of ersodetug was 9 days (range, 1-84); all patients hospitalized at baseline (n = 6) were discharged to home for treatment, including 2 who were previously considering hospice-level care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Within 8 weeks of ersodetug initiation, nearly all individuals (n = 7) were able to proceed with tumor-directed therapies, including chemotherapy (n = 7), surgery (n = 4), and other medical procedures such as hepatic arterial embolization (n = 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Response by starting dose
“Glycemic stabilization was achieved across dosing regimens, with a more pronounced response observed in individuals initiated at 9 mg/kg weekly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“More protracted responses to ersodetug and longer times to hospital discharge in initially treated individuals were associated with lower starting doses and less frequent administration of ersodetug (6 mg/kg and/or biweekly administration).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ENDO 2026 poster: 7 of 8 patients on parenteral glucose with at least 50% reduction
Glucose infusion rate, hospitalization, and performance status outcomes by patient in the company table of 9 patients
| Outcome | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | Patient 9 |
|---|---|---|---|---|---|---|---|---|---|
| Percent reduction in GIR by 8 weeks | “>50%, then 100% by 9 weeks” | “<50%” | “100%” | “100%” | “100%” | “n/a” | “100%” | “Unknown amount” | “100%” |
| Time to IV glucose discontinuation (days) | “74” | “139 (achieved 50% reduction)” | “4” | “5” | “2” | “n/a” | “3” | “n/a” | “42” |
| Hospitalized days in the 30 days after initiation | “30” | “0” | “7” | “8” | “8” | “0” | “16” | “30” | “1” |
| ECOG at month 3 | “0” | “2” | “0” | “0” | “0” | “0” | “1” | “5” | “0” |
Company summary: 75% of patients on IV dextrose or parenteral nutrition discontinued it
NANETS 2024 poster: 4 of 5 patients discontinued parenteral dextrose
Single published case: hypoglycemia, dextrose infusion, and discharge after ersodetug
“After the second RZ358 infusion (at a dose of 6 mg per kilogram of body weight), the hypoglycemia attenuated, with less than 1% of all sensor glucose values in each 24-hour period being less than 54 mg per deciliter, a result that permitted a reduction in the rate of dextrose infusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After four additional infusions of RZ358 (each at a dose of 9 mg per kilogram), metabolic stability allowed discontinuation of other therapies, despite persistent excessive insulin secretion, elevated lactate dehydrogenase level” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Initiation of the anti–insulin receptor monoclonal antibody RZ358 (day 0) was successful in reducing the frequency of hypoglycemia, and the patient was able to safely receive a second dose of LU (day 67), which allowed for discharge home on day 83 after initiation of RZ358 therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The patient has remained free of severe hypoglycemia after 9 months of RZ358 therapy, currently administered at monthly intervals, with no evidence of adverse effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Second patient: insulin-secreting cervical cancer
Health-related quality of life and patient-reported outcomes
No quality of life instrument: functional benefit reported as clinician-rated performance status
“With improvements in glycemic control, all individuals experienced associated functional benefits, including hospital discharge in previously prolonged inpatient cases, and marked improvements in ECOG performance status.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Resumption of daily activities, as stated by the company without a measurement instrument
Safety results
Serious adverse events and drug-related events in the peer-reviewed case series
“No drug-related serious adverse events were observed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ersodetug was generally safe and well tolerated among all individuals and across all dose levels and regimens.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no drug-related deaths, adverse drug reactions, discontinuations due to adverse events, treatment-emergent clinically significant laboratory abnormalities indicative of organ toxicity, or other dose-limiting toxicities, as determined by treating physicians and reviewed by the sponsor's safety committee.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As depicted in Table 4, 3 of 8 individuals experienced serious adverse events, all attributed to underlying tumor progression or tumor-directed therapies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment-emergent serious adverse events, pooled cohort of 8
| Measure | Pooled cohort (n = 8), number (%) |
|---|---|
| Individuals with serious TEAEs, n (%) | “3 (37.5%)”View highlighted excerpt for this quote |
| Total SAEs | “4”View highlighted excerpt for this quote |
| Individuals with PI-judged study drug-related SAEs, n (%) | “0 (0%)”View highlighted excerpt for this quote |
| Grade 1 (mild) | “1 (12.5%)”View highlighted excerpt for this quote |
| Grade 2 (moderate) | “0 (0%)”View highlighted excerpt for this quote |
| Grade 3 (severe) | “2 (25%)”View highlighted excerpt for this quote |
| Grade 4 (life-threatening) | “1 (12.5%)”View highlighted excerpt for this quote |
| Grade 5 (death) | “0 (0%)”View highlighted excerpt for this quote |
Disease progression not counted as an adverse event, and hyperglycemia
“Disease progression was not reported as a treatment-emergent adverse event, as per EAP treatment guidelines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A corresponding increase in time above 180 mg/dL was observed, but without associated clinical impact.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ENDO 2026 poster: no drug-related serious adverse events in 9 patients
Company statement on side effects
Study limitations
Summary
- Design: the peer-reviewed report is a retrospective case series of 8 individuals treated under single-patient compassionate use, with no control group. The authors used nominal P-values without formal or prespecified hypothesis testing, could not construct 95% intervals, and developed the statistical analysis plan after the primary analyses.
- Confounding: within 8 weeks of starting ersodetug, 7 individuals received chemotherapy, 4 had surgery, and 5 had other procedures such as hepatic arterial embolization, which can also reduce hypoglycemia. Doses and schedules changed during the program, and the first 2 individuals were treated under an earlier framework at a lower weekly dose.
- Inconsistent counts and data: the number of patients differs by source (5 in the NANETS 2024 poster, 8 in the publication, 9 in the company table and ENDO 2026 poster). The company table and the publication differ in a patient's sex (“F; 74” and “M / 74”), and the publication gives hospitalization at entry as “median, 28 days; range, 4-66 days” in its text while its table lists a longest stay of 49 days. A company release describes the 9 patients as having malignant insulinoma and non-islet cell tumors, while the case-level tables list insulin-secreting tumors.
- Overlap: the first patient's glucose data were previously published as a single case report, so that case is not independent evidence.
- Safety ascertainment: disease progression was not reported as an adverse event under the program guidelines.